Q-omics provides the consensus-scored LRRC37A17P profile across patient tissues and cancer cell-line models. LRRC37A17P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LRRC37A17P is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, LRRC37A17P RNA expression shows 21,501 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where LRRC37A17P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC37A17P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC37A17P survival associations across molecular data types. LRRC37A17P RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC37A17P RNA expression–survival associations across cancer types. High LRRC37A17P expression shows unfavorable associations in CESC and COAD, but favorable associations in KIRC, LGG, UCS and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LRRC37A17P RNA expression.
This table summarizes LRRC37A17P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC37A17P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC37A17P shows lower tumor expression in KICH, THCA, BLCA, UCEC and BRCA and higher tumor expression in LIHC. The KICH box plot shows higher LRRC37A17P RNA expression in normal versus tumor tissue (log2 FC = −1.235, t-test p < 0.001).
This table shows molecular features associated with LRRC37A17P in patient tissues and cancer cell lines. In patient samples, LRRC37A17P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
